TEVA PHARMACEUTICAL INDUSTRIES LTD - 8-K Filing

Teva recasts historical segment reporting and discloses $500M milestone payment for anti-TL1A Phase 3 studies in Q4 2025 (Items: 8.01 Other Events Teva Pharmaceutical Industries Limited (the “Company”) is filing this Current Report on Form 8-K to recast historical segment in, 9.01 Financial Statements and Exhibits)

SEC EDGAR · September 3, 2026, 20:27 UTC

Tickers: $TEVA

Read the full article at SEC EDGAR

More Regulatory news

CENTRUS ENERGY CORP - 8-K Filing SEC EDGAR · November 12, 2026, 14:09 UTC
SAGA COMMUNICATIONS INC - 8-K Filing SEC EDGAR · November 12, 2026, 14:05 UTC
NextBoat Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:05 UTC
CIVISTA BANCSHARES, INC. - 8-K Filing SEC EDGAR · November 12, 2026, 14:05 UTC
RF Acquisition Corp II - 10-Q Filing SEC EDGAR · November 12, 2026, 14:04 UTC
ORASURE TECHNOLOGIES INC - 10-Q Filing SEC EDGAR · November 12, 2026, 14:03 UTC
Rocket Companies, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:03 UTC
Applied Aerospace & Defense, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 14:02 UTC
Palomar Holdings, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:02 UTC
UNITED GUARDIAN INC - 10-Q Filing SEC EDGAR · November 12, 2026, 14:00 UTC